Nachrichten zur Xenon Pharmaceuticals Inc. Aktie

Eton Pharma (ETON) Q3 2025 Earnings Transcript

Image source: The Motley Fool.DATEThursday, November 6, 2025 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Sean BrynjelsenChief Financial Officer…

Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Earnings Call Transcript

…

Algernon Pharmaceuticals Completes Name Change to Algernon Health

VANCOUVER, British Columbia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN)…

Xenon Pharmaceuticals Inc. (XENE) Nav1.7 And Kv7 Programs Investor Webinar Transcript

…

Algernon Announces Preferred Share Class Approved at Annual and Special Meeting

VANCOUVER, British Columbia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:…

Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -900.00% and +13.24%, respectively, for the quarter ended June 2025. Do…

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused…

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

Xenon Pharmaceuticals (XENE) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition

VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:…

Eton Pharmaceuticals, Inc. (ETON) Q1 2025 Earnings Call Transcript

…

Eton Pharmaceuticals, Inc. (ETON) Q1 Earnings Lag Estimates

Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -22.22% and 6.71%, respectively, for the quarter ended March 2025. Do…

Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript

…

Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 48.2% in Xenon Pharmaceuticals (XENE).…

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Eton Pharmaceuticals, Inc. (ETON) Virtual Investor Day and Q4 2024 Earnings Call Transcript

…

Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript

…

Xenon Pharmaceuticals: 2025 Could Be Pivotal For Azetukalners Epilepsy Potential

…

Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference

VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused…

Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®

DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON),…

Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript

…

Deep Track Capitals Strategic Investment in Reneo Pharmaceuticals

On October 4, 2024, Deep Track Capital, LP (Trades, Portfolio) marked a significant portfolio addition by acquiring 68,415.6 shares of…

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON),…

Earnings call: Xenon Pharmaceuticals Q2 2024 results and clinical updates By Investing.com

Earnings call: Xenon Pharmaceuticals Q2 2024 results and clinical updates…

Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain

…

Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript

…

Algernon Pharmaceuticals Announces Closing of Private Placement

VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the…

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON),…

Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript

…

Xenon Pharmaceuticals Inc. (XENE) Q1 2024 Earnings Call Transcript

…

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON),…

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN)…

Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting

VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced…

Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Researchs Pitch, Deep Dive and Q&A Webinar on April 16th, 2024

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:…